How many stocks are there of AnGes?
The current number of stocks of AnGes is 189.28 M undefined.
AnGes Stocks 2024
AnGes Stocks
189.28 M
Ticker
4563.T
ISIN
JP3127700007
WKN
779518
In 2024, AnGes had 189.28 M outstanding stocks, a 21.29% change from the 156.05 M stocks in the previous year.
The AnGes Stocks history
| YEAR | NUMBER OF STOCKS (undefined JPY) |
|---|---|
| 2023 | 189.28 |
| 2022 | 156.05 |
| 2021 | 147.27 |
| 2020 | 119.15 |
| 2019 | 104.73 |
| 2018 | 86.96 |
| 2017 | 76.24 |
| 2016 | 63.44 |
| 2015 | 55.6 |
| 2014 | 38.1 |
| 2013 | 35.4 |
| 2012 | 29.8 |
| 2011 | 28.7 |
| 2010 | 27.8 |
| 2009 | 27.8 |
| 2008 | 27.7 |
| 2007 | 26.9 |
| 2006 | 24.3 |
| 2005 | 23.5 |
| 2004 | 22.6 |
AnGes shares outstanding JP3127700007 · 779518
The number of shares was AnGes in 2023 — This indicates how many shares 189.277 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue AnGes earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates AnGes's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of AnGes’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AnGes's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 22.6 M Aktien |
| 2005 | 23.5 M Aktien |
| 2006 | 24.3 M Aktien |
| 2007 | 26.9 M Aktien |
| 2008 | 27.7 M Aktien |
| 2009 | 27.8 M Aktien |
| 2010 | 27.8 M Aktien |
| 2011 | 28.7 M Aktien |
| 2012 | 29.8 M Aktien |
| 2013 | 35.4 M Aktien |
| 2014 | 38.1 M Aktien |
| 2015 | 55.6 M Aktien |
| 2016 | 63.44 M Aktien |
| 2017 | 76.24 M Aktien |
| 2018 | 86.96 M Aktien |
| 2019 | 104.73 M Aktien |
| 2020 | 119.15 M Aktien |
| 2021 | 147.27 M Aktien |
| 2022 | 156.05 M Aktien |
| 2023 | 189.28 M Aktien |
AnGes Aktienanalyse
What does AnGes do?
AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating AnGes's Shares Outstanding
AnGes's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in AnGes’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding AnGes’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in AnGes’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about AnGes stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of AnGes are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of AnGes evolved in recent years?
The number of shares of AnGes has increased by 21.29% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. AnGes as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of AnGes?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does AnGes pay?
Over the past 12 months, AnGes paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnGes is expected to pay a dividend of 0 JPY.
What is the dividend yield of AnGes?
The current dividend yield of AnGes is .
When does AnGes pay dividends?
AnGes pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AnGes?
AnGes paid dividends every year for the past 0 years.
What is the dividend of AnGes?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is AnGes located?
AnGes is assigned to the 'Health' sector.
Wann musste ich die Aktien von AnGes kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AnGes from 11/27/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 11/27/2024.
When did AnGes pay the last dividend?
The last dividend was paid out on 11/27/2024.
What was the dividend of AnGes in the year 2023?
In the year 2023, AnGes distributed 0 JPY as dividends.
In which currency does AnGes pay out the dividend?
The dividends of AnGes are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AnGes
Our stock analysis for AnGes Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnGes Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
